{"nctId":"NCT00931632","briefTitle":"Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants","startDateStruct":{"date":"2009-11"},"conditions":["Bronchopulmonary Dysplasia"],"count":451,"armGroups":[{"label":"Inhaled Nitric Oxide","type":"EXPERIMENTAL","interventionNames":["Drug: Inhaled Nitric Oxide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Inhaled Nitric Oxide","otherNames":["INOmax"]},{"name":"Placebo","otherNames":["Nitrogen gas"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Preterm infants who are:\n\n  1. 500 to 1250 grams at birth\n  2. \\< 30 weeks gestational age\n  3. 5 to 14 days of age (inclusive) at the time of entry\n  4. Requiring mechanical ventilation or for those infants â‰¤ 800 grams, positive pressure support (including CPAP) for respiratory insufficiency on days 5 to 14 days of age (inclusive)\n\nExclusion Criteria:\n\n1. Preterm infants with life-threatening anomalies (cranial, cardiac, thoracic, chromosomal) or congenital diaphragmatic hernia with lung hypoplasia, or any subject who will not receive complete intensive care\n2. Preterm infants with bilateral Grade 4 intraventricular hemorrhage (IVH)\n3. Subjects who are dependent on right to left shunting to maintain the systemic circulation\n4. Preterm infants who received prior iNO therapy\n5. Use of another investigational agent","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Days","maximumAge":"14 Days","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Survival Without BPD at 36 Weeks","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]}]},{"type":"SECONDARY","title":"Days of Airway Pressure Support - Intent-to-treat Population","description":"Airway pressure support includes conventional mechanical ventilation, conventional, high frequency oscillatory ventilation, jet, continuous positive airway pressure, and other.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":"42.16"},{"groupId":"OG001","value":"55.3","spread":"40.45"}]}]}]},{"type":"SECONDARY","title":"Length of Birth Hospitalization","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108.3","spread":"54.03"},{"groupId":"OG001","value":"105.0","spread":"36.69"}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Use of Postnatal Corticosteroids for Bronchopulmonary Dysplasia","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Use of Postnatal Corticosteroids for Any Medical Reason","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]}]},{"type":"SECONDARY","title":"Systemic Use of Postnatal Corticosteroids for Any Medical Reason","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Oxygen Use","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":"59.26"},{"groupId":"OG001","value":"88.0","spread":"40.91"}]}]}]},{"type":"SECONDARY","title":"Severity of Bronchopulmonary Dysplasia","description":"Severity of bronchopulmonary dysplasia defined by the fraction of inspired O2 concentration (FiO2) requirement.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":105,"n":229},"commonTop":["Hyponatraemia","Metabolic acidosis","Bronchopulmonary dysplasia","Pulmonary edema","Feeding disorder neonatal"]}}}